285 related articles for article (PubMed ID: 33844132)
1. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study.
Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Xie D; Yang YX
Adv Ther; 2021 May; 38(5):2586-2598. PubMed ID: 33844132
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Medvedeva E; Xie D; Yang YX
Inflamm Bowel Dis; 2022 May; 28(5):734-744. PubMed ID: 34245261
[TBL] [Abstract][Full Text] [Related]
3. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
Bye WA; Jairath V; Travis SPL
Aliment Pharmacol Ther; 2017 Jul; 46(1):3-15. PubMed ID: 28449273
[TBL] [Abstract][Full Text] [Related]
4. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
Park KT; Sceats L; Dehghan M; Trickey AW; Wren A; Wong JJ; Bensen R; Limketkai BN; Keyashian K; Kin C
Aliment Pharmacol Ther; 2018 Aug; 48(3):340-346. PubMed ID: 29876995
[TBL] [Abstract][Full Text] [Related]
5. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.
Guo D; Jiang K; Hong J; Zhang M; Shi Y; Zhou B
Int J Colorectal Dis; 2021 Oct; 36(10):2081-2092. PubMed ID: 34467414
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
9. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.
Choi S; Kim ES; Kwon Y; Kim MJ; Choe YH; Choe BH; Kang B
J Korean Med Sci; 2022 Sep; 37(37):e282. PubMed ID: 36163478
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients.
Ruscio MD; Tinazzi I; Variola A; Geccherle A; Marchetta A; McGonagle D
Rheumatology (Oxford); 2021 Dec; 60(12):5809-5813. PubMed ID: 33580246
[TBL] [Abstract][Full Text] [Related]
12. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Pneumonia, Related Hospitalization, and Mortality Among Younger Unvaccinated IBD Patients in a Nationwide Cohort.
Khan N; Trivedi C; Shah Y; Patel M; Sundararajan R; Xie D; Yang YX
J Clin Gastroenterol; 2024 Mar; 58(3):277-280. PubMed ID: 37252728
[TBL] [Abstract][Full Text] [Related]
14. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Vedamurthy A; Gangasani N; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
Ramos GP; Dimopoulos C; McDonald NM; Janssens LP; Hung KW; Proctor D; Ruggiero E; Kane S; Bruining DH; Faubion WA; Raffals LE; Loftus EV; Al-Bawardy B
Inflamm Bowel Dis; 2021 Jul; 27(8):1270-1276. PubMed ID: 33165569
[TBL] [Abstract][Full Text] [Related]
17. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
18. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
[TBL] [Abstract][Full Text] [Related]
19. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease.
Yung DE; Horesh N; Lightner AL; Ben-Horin S; Eliakim R; Koulaouzidis A; Kopylov U
Inflamm Bowel Dis; 2018 Oct; 24(11):2327-2338. PubMed ID: 29788385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
